Skip to main content
. 2008 Apr 13;68(3):367–372. doi: 10.1136/ard.2007.076760

Table 3. Univariate analysis predicting all cause and cardiovascular disease mortality.

Patients n Person time intervals All cause mortality CVD mortality
Univariate, OR (95% CI) Adjusted age and gender, OR (95% CI) Univariate, OR (95% CI) Adjusted age and gender, OR (95% CI)
Baseline NSAID use All 923 5634 0.73 (0.55 to 0.99) 0.81 (0.60 to 1.03) 0.67 (0.43 to 1.04) 0.73 (0.48 to 1.15)
Females 599 3742 0.86 (0.56 to 1.32) 0.86 (0.55 to 1.32) 0.55 (0.30 to 1.02) 0.54 (0.29 to 1.02)
Males 324 1892 0.61 (0.41 to 0.92) 0.74 (0.50 to 1.12) 0.79 (0.42 to 1.47) 0.94 (0.50 to 1.78)
Ever NSAID use All 923 5634 0.62 (0.44 to 0.86) 0.70 (0.50 to 1.00) 0.48 (0.29 to 0.77) 0.54 (0.33 to 0.88)
Females 599 3742 0.74 (0.44 to 1.22) 0.81 (0.48 to 1.36) 0.42 (0.22 to 0.82) 0.46 (0.23 to 0.90)
Males 324 1892 0.49 (0.31 to 0.77) 0.61 (0.39 to 0.98) 0.50 (0.25 to 1.01) 0.62 (0.31 to 1.27)
Time-varying NSAID use All 923 5634 0.58 (0.43 to 0.78) 0.66 (0.49 to 0.90) 0.51 (0.32 to 0.81) 0.58 (0.37 to 0.93)
Females 599 3742 0.60 (0.39 to 0.91) 0.68 (0.44 to 1.05) 0.50 (0.26 to 0.97) 0.58 (0.30 to 1.12)
Males 324 1892 0.54 (0.36 to 0.81) 0.65 (0.43 to 0.98) 0.51 (0.27 to 0.94) 0.59 (0.31 to 1.12)

CVD, cardiovascular disease; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio.